Stratos BioCapital is proud to announce the launch of ImmunaGenix, a next-generation biotech company focused on developing precision immunotherapies for autoimmune diseases and cancer. Backed by Stratos, ImmunoGenix is pioneering novel approaches to immune modulation, leveraging advanced antibody engineering and cellular therapy platforms.
A New Era in Immunotherapy
ImmunoGenix is dedicated to tackling some of the most challenging autoimmune and oncology indications by developing targeted immune-modulating therapies that restore balance to the immune system. The company’s lead program, IGX-101, is a first-in-class biologic designed to selectively suppress overactive immune responses while preserving normal immune function – an approach that could transform the treatment landscape for diseases like lupus, multiple sclerosis, and rheumatoid arthritis.
Strategic Vision & Scientific Expertise
Stratos BioCapital Managing Partner Rahul Dev emphasized the importance of ImmunoGenix’s mission:
“With a rapidly growing understanding of immune system dysregulation, there is an unprecedented opportunity to develop safer, more effective therapies. ImmunoGenix is at the forefront of this innovation, and we are thrilled to support their journey.”
Led by a world-class team of immunologists and biotech executives, ImmunoGenix aims to accelerate its pipeline toward clinical trials over the next two years.
Looking Ahead
With Stratos BioCapital’s backing, ImmunaGenix will continue advancing its research and expanding strategic collaborations. The company is currently building out its research facilities and plans to engage with regulatory agencies in preparation for its first-in-human trials.
For more information, visit https://stratosbiocapital.com or email info@stratosbiocapital.com.